These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 287555)

  • 21. Anthracycline analogs: re-assessments and prospects.
    Carter SK
    Cancer Treat Rep; 1979 May; 63(5):935-6. PubMed ID: 455336
    [No Abstract]   [Full Text] [Related]  

  • 22. A new antitumor antibiotic, carminomycin (NSC-180024).
    Gause GF; Brazhnikova MG; Shorin VA
    Cancer Chemother Rep; 1974; 58(2):255-6. PubMed ID: 4830498
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
    Wadler S; Fuks JZ; Wiernik PH
    J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro studies on anthracycline haloderivatives.
    Facchinetti T; Geroni C; Fumagalli A; Giuliani FC
    Drugs Exp Clin Res; 1986; 12(8):657-61. PubMed ID: 3463498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.
    Ando S; Sasada M; Uchino H; Kagawa D; Ueda T; Nakamura T
    Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2343-55. PubMed ID: 3471823
    [No Abstract]   [Full Text] [Related]  

  • 26. Lethal effect of adriamycin on the division cycle of HeLa cells.
    Kim SH; Kim JH
    Cancer Res; 1972 Feb; 32(2):323-5. PubMed ID: 5058189
    [No Abstract]   [Full Text] [Related]  

  • 27. New anthracycline glycosides obtained by the nitrous acid deamination of daunorubicin, doxorubicin and their configurational analogues.
    Cassinelli G; Ballabio M; Arcamone F; Casazza AM; Podesta' A
    J Antibiot (Tokyo); 1985 Jul; 38(7):856-67. PubMed ID: 3861603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture.
    Arcamone F
    Cancer Res; 1985 Dec; 45(12 Pt 1):5995-9. PubMed ID: 3864526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Models of preclinical studies of anthracyclines].
    Fizames C
    Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA damage by anthracycline drugs in human leukemia cells.
    Schwartz HS; Kanter PM
    Cancer Lett; 1981 Sep; 13(4):309-13. PubMed ID: 6946856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anthracycline derivatives in new drug development programs.
    Rozencweig M; De Sloover C; Von Hoff DD; Tagnon HJ; Muggia FM
    Cancer Treat Rep; 1979 May; 63(5):807-8. PubMed ID: 455322
    [No Abstract]   [Full Text] [Related]  

  • 32. Antileukemic activity of synthetic daunomycinone derivatives bearing modifications in the glycosidic moiety.
    Perchellet EM; Sperfslage BJ; McIlvain CJ; Aligiannis N; Pouli N; Marakos P; Skaltsounis AL; Perchellet JP
    Anticancer Res; 2001; 21(6A):3957-67. PubMed ID: 11911277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics.
    Studzian K; Wasowska M; Piestrzeniewicz MK; Wilmańska D; Szmigiero L; Oszczapowicz I; Gniazdowski M
    Neoplasma; 2001; 48(5):412-8. PubMed ID: 11845988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A murine model to evaluate the ability of in vitro clonogenic assays to predict the response to tumors in vivo.
    Mirabelli CK; Sung CM; McCabe FL; Faucette LF; Crooke ST; Johnson RK
    Cancer Res; 1988 Oct; 48(19):5447-54. PubMed ID: 3046738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of the structure of new anthracycline antibiotics on their biological properties.
    Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
    Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
    Faderl S; Estrov Z; Kantarjian HM; Harris D; Van Q; Fokt I; Przewloka T; Godlewski C; Woynarowski JM; Priebe W
    Anticancer Res; 2001; 21(6A):3777-84. PubMed ID: 11911247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
    Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based design of a new bisintercalating anthracycline antibiotic.
    Chaires JB; Leng F; Przewloka T; Fokt I; Ling YH; Perez-Soler R; Priebe W
    J Med Chem; 1997 Jan; 40(3):261-6. PubMed ID: 9022792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.
    Warrell RP
    Drugs Exp Clin Res; 1986; 12(1-3):275-82. PubMed ID: 3525076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo.
    Tapiero H; Munck JN; Fourcade A
    Drugs Exp Clin Res; 1986; 12(1-3):257-64. PubMed ID: 3460752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.